← Back to the fund page Use your browser's print dialog and choose “Save as PDF”. A4, two pages.
InvestVerdict

DSP Healthcare Fund

Direct Plan · IDCW · Sectoral / Thematic · Scheme code 145455

NAV₹29.7970as on 28 Aug 2026
Fund houseDSP Mutual Fund
CategorySectoral / Thematic
Plan & optionDirect · IDCW
History7.7 years

Returns (%)

 1M3M6M1Y3Y5Y7Y10YLaunch
This scheme 3.7813.0821.53 9.8312.796.49 17.13—15.08
Nifty 500
benchmark		 0.874.312.15 5.2012.4911.41 ——15.49
Sectoral / Thematic
category median		 ——— 6.9716.9114.34 —15.17—

Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published NAV history for this scheme.

Risk

 VolatilitySharpeSortinoBetaAlphaMax fallR²
This scheme 16.2% 0.39 0.50 0.65 5.87% -28.8% 37.81
Nifty 500
benchmark		 17.2%0.35 0.47—— -37.3%—

Risk-free rate 6.5%. Beta, alpha and R² are regressed on the 83 months this scheme and its benchmark share.

Growth of ₹100 since launch

801632473302020202220242026InvestVerdict

Drawdown from peak (%)

0%-11%-22%-32%2020202220242026

Every one-year period it has lived through

WindowsWorstMedianBestPeriods that lost money
328 -22.3% 13.0% 91.5% 29%

Every one-year holding period in this scheme's history, not just the last one — the spread a real investor would have met depending only on when they started.

InvestVerdict

DSP Healthcare Fund

Direct Plan · IDCW

Allocation

By asset

Equity76.05%
Foreign Securities17.19%
Cash & Equivalents6.76%

By market cap

Large Cap21.30%
Mid Cap12.02%
Small Cap42.73%
Unclassified17.19%

Concentration

Number of stocks29
Top 5 stocks39.17%
Top 10 stocks63.97%
Top 20 stocks87.10%
Largest holding8.35%
Largest sectorPharmaceuticals & Biotechnology 61.18%
Effective stocks20.0
Cash6.76%
InvestVerdict

DSP Healthcare Fund

Direct Plan · IDCW · holdings

Top 18 holdings

#CompanySector% of fund
1— Pharmaceuticals & Biotechnology8.35%
2— Pharmaceuticals & Biotechnology8.21%
3— Pharmaceuticals & Biotechnology8.14%
4— Unclassified7.64%
5— Healthcare Services7.59%
6— Pharmaceuticals & Biotechnology6.88%
7— Pharmaceuticals & Biotechnology6.54%
8— Healthcare Equipment & Supplies5.72%
9— Healthcare Services4.81%
10— Pharmaceuticals & Biotechnology4.13%
11— Healthcare Services3.60%
12— Pharmaceuticals & Biotechnology3.38%
13— Pharmaceuticals & Biotechnology2.87%
14— Healthcare Services2.87%
15— Pharmaceuticals & Biotechnology2.61%
16— Pharmaceuticals & Biotechnology2.53%
17— Pharmaceuticals & Biotechnology2.21%
18— Healthcare Equipment & Supplies2.01%

Sector split

Pharmaceuticals & Biotechnology — 61.2%Healthcare Services — 22.0%Healthcare Equipment & Supplies — 7.9%Cash & Equivalents — 6.8%Other — 2.1%Pharmaceuticals & Biotech…61.2%Healthcare Services22.0%Healthcare Equipment & Su…7.9%Cash & Equivalents6.8%Other2.1%
Pharmaceuticals & Biotechnology61.18%
Healthcare Services22.01%
Healthcare Equipment & Supplies7.91%
Cash & Equivalents6.76%
Insurance1.20%
Foreign Security0.94%

A ₹10,000 monthly SIP over five years

InvestedValueGainXIRR
₹600,000 ₹789,854 ₹189,854 10.95%

XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has been invested for a different length of time.

Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past returns do not predict future ones. Generated 29 Aug 2026.